ArticleFrontiers in oncology2026
Pathological characteristics of cervical lymph node metastases in papillary thyroid carcinoma compared with lung adenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: US-guided thermal ablation (TA) has shown favorable local control for cervical lymph node metastases (LNM) from papillary thyroid carcinoma (PTC), whereas outcomes appear less favorable for LNM from lung adenocarcinoma (LAC). The pathological basis underlying these differences remains unclear. Purpose: To compare the pathological characteristics of cervical LNMs from PTC and LAC, focusing on proliferation- and invasion-related markers, and to explore potential biological factors associated with their distinct clinical behavior. Methods: In this single-center retrospective study, cervical LNM specimens from patients with PTC or LAC were assessed by immunohistochemistry for Ki-67, PCNA, p53, and MMP-9. Marker expression in tumor cells was compared between groups. Results: A total of 145 patients were included (PTC-N1a, n = 50; PTC-N1b, n = 50; LAC-LNM, n = 45). LAC-related lymph node metastases (LAC-LNM) showed significantly higher Ki-67, PCNA, p53, and MMP-9 staining intensity than both PTC subgroups (all overall P < 0.001). The proportion of MMP-9-positive tumor cells also differed among groups (P = 0.016). Within the PTC cohort, only Ki-67 expression was significantly higher in N1b than in N1a (P = 0.001). After adjustment for age and sex, LAC-LNM remained associated with higher Ki-67, PCNA, and p53 expression and greater MMP-9 staining intensity, whereas the difference in MMP-9-positive tumor cell proportion was no longer significant. Conclusion: LAC-LNM exhibited a more proliferative immunophenotype and greater MMP-9 staining intensity than PTC-LNM. These differences may contribute to their distinct clinical behavior.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.